Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient

Anesthesia and Analgesia

Volumn 107, Issue 4, 2008, Pages 1380-1383

  Grande, Lucinda A ^a   O'Donnell, Brendan R ^a   Fitzgibbon, Dermot R ^a   Terman, Gregory W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; HYDROMORPHONE; KETAMINE; KETOROLAC; LORAZEPAM; MEMANTINE; METHADONE; MORPHINE; NAPROXEN; OPIATE; OXYCODONE; ANALGESIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CANCER PATIENT; CASE REPORT; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPHORIA; HALLUCINATION; HOSPITAL PATIENT; HUMAN; LAMINECTOMY; LEG PAIN; LIPOSARCOMA; LOW BACK PAIN; LOW DRUG DOSE; LUNG METASTASIS; MALE; MEMORY DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PAIN ASSESSMENT; PRIORITY JOURNAL; SOMNOLENCE; SPINE METASTASIS; TREATMENT FAILURE; DRUG ANTAGONISM; INTRACTABLE PAIN; METASTASIS; SPINAL CORD TUMOR;

ADULT; ANALGESICS; ANALGESICS, OPIOID; DRUG TOLERANCE; HUMANS; KETAMINE; LIPOSARCOMA; MALE; MEMANTINE; PAIN MEASUREMENT; PAIN, INTRACTABLE; RECEPTORS, N-METHYL-D-ASPARTATE; SPINAL NEOPLASMS;

EID: 53449101070     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181733ddd     Document Type: Article

References (40)

1. Rapp SE, Ready LB, Nessly ML. Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain 1995;61:195-201
2. Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurology 2002;58:554-63
3. Yang CY, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth 1996;43:379-83
4. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246-52
5. Celerier E, Laulin JP, Corcuff JB, Le Moal, M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci 2001;21:4074-80
6. Mayer DJ, Mao J, Price DD. The development of morphine tolerance and dependence is associated with translocation of protein kinase C. Pain 1995;61:365-74
7. Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on NMDA receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991;44:293-9
8. Yamamoto T, Yaksh TL. Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve: excitatory amino acid antagonists. Pain 1992;49:121-8
9. Saito O, Aoe T, Kozikowski A, Sarva J, Neale JH, Yamamoto T. Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. Can J Anaesth 2006;53: 891-8
10. Hao JX, Xu XJ. Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered excitatory amino acid receptor antagonists. Pain 1996;66:279-85
11. Galer BS, Lee D, Ma T, Nagle B, Schlagheck TG. MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain 2005;115:284-95
12. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis 2004;6:S61-S74
13. Schley M, Topfner S, Wiech K, Schaller HE, Konrad CJ, Schmelz M, Birbaumer N. Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. Eur J Pain 2007;11:299-308
14. Sinis N, Birbaumer N, Gustin S, Schwarz A, Bredanger S, Becker ST, Unertl K, Schaller HE, Haerle M. Memantine treatment of complex regional pain syndrome: a preliminary report of six cases. Clin J Pain 2007;23:237-43
15. Eisenberg E, Kleiser A, Dortort A, Haim T, Yarnitsky D. The NMDA (N-methyl-d-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur J Pain 1998;2:321-7
16. Maier C, Dertwinkel R, Mansourian N, Hosbach I, Schwenkreis P, Senne I, Skipka G, Zenz M, Tegenthoff M. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain-results of a randomized double-blinded, placebo-controlled trial. Pain 2003;103:277-83
17. Nikolajsen L, Gottrup H, Kristensen AG, Jensen TS. Memantine (a N-methyl-d-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg 2000;91:960 - 6
18. Wiech K, Kiefer RT, Töpfner S, Preissl H, Braun C, Unertl K, Flor H, Birbaumer N. A placebo-controlled randomized crossover trial of the N-methyl-d-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth Analg 2004;98:408-13
19. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-d-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999;289:1048-53
20. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999;82:111-25
21. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004;99:482-95
22. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995;62:259-74
23. Zeng J, Thomson LM, Aicher SA, Terman GW. Primary afferent NMDA receptors increase dorsal horn excitation and mediate opiate tolerance in neonatal rats. J Neurosci 2006;26:12033-42
24. Guntz E, Dumont H, Roussel C, Gall D, Dufrasne F, Cuvelier L, Blum D, Schiffmann SN, Sosnowski M. Effects of remifentanil on N-methyl-d- aspartate receptor: an electrophysiologic study in rat spinal cord. Anesthesiology 2005;102:1235-41
25. Yezierski RP, Park SH. The mechanosensitivity of spinal sensory neurons following intraspinal injections of quisqualic acid in the rat. Neurosci Lett 1993;157:115-19
26. Fairbanks CA, Schreiber KL, Brewer KL, Yu CG, Stone LS, Kitto KF, Nguyen HO, Grocholski BM, Shoeman DW, Kehl LJ, Regunathan S, Reis DJ, Yezierski RP, Wilcox GL. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci USA 2000;97:10584-9
27. Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, Clohisy DR, Mantyh PW. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000;98:585-98
28. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci 2005; 28:661-9
29. Tan-No K, Esashi A, Nakagawasai O, Niijima F, Tadano T, Sakurada C, Sakurada T, Bakalkin G, Terenius L, Kisara K. Intrathecally administered big dynorphin, a prodynorphinderived peptide, produces nociceptive behavior through an N-methyl-d-aspartate receptor mechanism. Brain Res 2002;952: 7-14
30. Zhang RX, Li A, Liu B, Wang L, Ren K, Zhang H, Berman BM, Lao L. IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats. Pain 2008;135:232-9
31. Terman GW, Jin W, Cheong YP, Lowe J, Caron MG, Lefkowitz RJ, Chavkin C. G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol 2004;141:55-64
32. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006;104:570-87
33. Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan TP Jr, Lai J, Porreca F. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002;22:6747-55
34. Song P, Zhao ZO. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001;39: 281- 6
35. Laughlin TM, Vanderah TW, Lashbrook J, Nichols ML, Ossipov M, Porreca F, Wilcox GL. Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain 1997;72:253-60
36. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994;14:2301-12
37. Johnston IN, Westbrook RF. Inhibition of morphine analgesia by LPS: role of opioid and NMDA receptors and spinal glia. Behav Brain Res 2005;156:75-83
38. Thomson LS, Zeng J, Terman GW. Increased endocannabinoid inhibition in the morphine-tolerant neonatal spinal cord slice. Soc Neurosci Abstr 2006;643.9/R13
39. Kawamata M, Watanabe H, Nishikawa K, Takahashi T, Kozuka Y, Kawamata T, Omote Namiki. Different mechanisms of development and maintenance of experimental incision-induced hyperalgesia in human skin. Anesthesiology 2002;97:550-9
40. Zahn PK, Brennan TJ. Lack of effect of intrathecally administered N-methyl-d-aspartate receptor antagonists in a rat model for postoperative pain. Anesthesiology 1998;88:143-56